Opportunity Information: Apply for CDC RFA GH12 1202
Apply for CDC RFA GH12 1202
- The Centers for Disease Control and Prevention in the health sector is offering a public funding opportunity titled "Onchocerciasis Elimination in the Americas" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.283 Centers for Disease Control and PreventionInvestigations and Technical Assistance.
- This funding opportunity was created on Dec 13, 2011 and posted on Dec 13, 2011.
- Applicants must submit their applications by Jan 17, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $15,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $3,000,000.00 in funding.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- The applicant eligible for this funding opportunity is the Carter Center, a 501 (c) (3) charitable organization. Please see the full announcement document for further information. No other applications are solicited.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "Onchocerciasis Elimination in the Americas" (Funding Opportunity Number CDC-RFA-GH12-1202) was a CDC discretionary funding announcement designed to push the Americas closer to eliminating onchocerciasis (river blindness). The program focus was to support the Onchocerciasis Elimination Program for the Americas (OEPA) in finishing the core public health work needed to stop transmission in remaining endemic areas and then verify that elimination has been achieved. In practical terms, the CDC intended this funding to help maintain the operational capacity for coordinated elimination activities across affected countries and to help generate the surveillance evidence required for World Health Organization (WHO) certification.
The work emphasized two connected strategies. First, it aimed to interrupt transmission of the parasite by sustaining semi-annual mass drug administration of Mectizan (ivermectin) in endemic communities. This twice-yearly distribution schedule is a standard elimination approach because it reduces the number of parasites in infected people and, over time, breaks the transmission cycle involving blackfly vectors. Second, the opportunity prioritized post-treatment epidemiological surveillance in each transmission focus. This surveillance component is critical because elimination is not only about stopping treatment; it is about demonstrating, through accepted monitoring methods, that transmission has been interrupted and remains interrupted long enough to justify moving toward elimination certification. The announcement explicitly tied these activities to preparation for WHO elimination certification, signaling that the expected outputs were not just programmatic (doses delivered) but also evidentiary (surveillance findings that meet certification standards).
The funding mechanism was a cooperative agreement, which typically means the CDC expected to have substantial involvement in the funded activities, such as collaborating on technical direction, monitoring performance, and aligning implementation with CDC and global health priorities. The award type sat within the "Health" activity category, and the listing indicated an expectation of a single award. The estimated total funding amount was $15,000,000, with an anticipated annual award range indicated by an award floor of $2,500,000 and an award ceiling of $3,000,000. No cost sharing or matching funds were required, reducing barriers on the recipient side and reflecting the public health urgency and the specialized nature of the work.
A notable feature of this opportunity is that it was essentially a sole-eligible-applicant announcement. The eligibility section specified that the only eligible applicant was The Carter Center, identified as a 501(c)(3) charitable organization, and the notice stated that no other applications were solicited. That structure suggests the CDC viewed the Carter Center as uniquely positioned to carry out the OEPA-aligned elimination work at the required scale and with the necessary partnerships, experience, and regional footprint. For anyone reading this as a general funding opportunity, it is important to understand it functioned more like a directed cooperative agreement than an open competition.
The grant was also framed as supporting the Global Health Initiative (GHI) target of eliminating onchocerciasis in Latin America by 2016. That timeline signals the program was intended to fund late-stage elimination tasks: sustaining high-coverage ivermectin distributions where transmission risk persisted, tightening operational quality, and expanding the intensity and rigor of surveillance as foci approached stopping treatment and moving into post-treatment monitoring. This endgame phase typically involves careful field coordination, strong data systems, entomological and epidemiological assessments, and rapid response capacity if indicators suggest residual transmission.
Administratively, the opportunity was posted and created on December 13, 2011, with an original and current closing date of January 17, 2012, and an archive date of February 16, 2012, meaning it is no longer active. The CFDA number associated with the program was 93.283 (CDC Investigations and Technical Assistance). For technical issues accessing the full announcement, the contact listed was the CDC Procurement and Grants Office Technical Information Management Section (TIMS) at 770-488-2700, indicating the standard federal grant support channel for announcement access problems rather than programmatic questions.
In short, this CDC cooperative agreement was built to finance the final stretch of onchocerciasis elimination work in the Americas: keep semi-annual ivermectin distribution on track in endemic zones, strengthen and carry out post-treatment surveillance in each focus, and compile the evidence base needed for WHO certification, all aligned to the then-current regional elimination goal for 2016.
FAQs: Onchocerciasis Elimination in the Americas (CDC-RFA-GH12-1202)
What is the name of this grant opportunity and its funding opportunity number?
The opportunity is titled "Onchocerciasis Elimination in the Americas" and the Funding Opportunity Number is CDC-RFA-GH12-1202.
What public health issue does this opportunity address?
It supports efforts to eliminate onchocerciasis (river blindness) in the Americas by stopping transmission in remaining endemic areas and generating evidence needed to verify elimination.
What was the main purpose of the funding?
The main purpose was to support the Onchocerciasis Elimination Program for the Americas (OEPA) in completing the core operational work required to interrupt transmission and then verify that elimination has been achieved, including preparation for World Health Organization (WHO) elimination certification.
Which program or initiative was this funding intended to support?
The funding was intended to support OEPA and its coordinated elimination activities across affected countries in the Americas.
What are the two primary strategies emphasized in the announcement?
The announcement emphasized (1) interrupting transmission by sustaining semi-annual mass drug administration (MDA) of Mectizan (ivermectin) in endemic communities, and (2) conducting post-treatment epidemiological surveillance in each transmission focus to demonstrate that transmission has been interrupted and remains interrupted.
What drug distribution approach was specifically highlighted?
The opportunity highlighted semi-annual (twice-yearly) mass drug administration of Mectizan (ivermectin) in endemic communities.
Why is twice-yearly ivermectin distribution important in this program design?
Twice-yearly distribution is described as a standard elimination approach because it reduces the number of parasites in infected people and, over time, helps break the transmission cycle involving blackfly vectors.
What kind of surveillance work did the opportunity prioritize?
It prioritized post-treatment epidemiological surveillance in each transmission focus. The emphasis was on producing accepted monitoring evidence showing transmission has been interrupted and remains interrupted long enough to support movement toward elimination certification.
How does WHO certification relate to the expected outcomes?
The announcement explicitly tied activities to preparation for WHO elimination certification, indicating that expected outputs included both program implementation (such as sustaining distributions) and evidentiary outputs (surveillance findings that meet certification standards).
What type of award mechanism was used?
The funding mechanism was a cooperative agreement.
What does it mean that the award was a cooperative agreement in this context?
In this context, a cooperative agreement indicates the CDC expected substantial involvement in the funded activities, such as collaboration on technical direction, performance monitoring, and alignment with CDC and global health priorities.
What activity category was associated with this funding?
The award type sat within the "Health" activity category.
How many awards were expected?
The listing indicated an expectation of a single award.
What was the estimated total funding amount?
The estimated total funding amount was $15,000,000.
What was the anticipated annual award range?
The anticipated annual award range was reflected by an award floor of $2,500,000 and an award ceiling of $3,000,000.
Was cost sharing or matching required?
No. The announcement stated that no cost sharing or matching funds were required.
Who was eligible to apply for this opportunity?
The eligibility section specified that the only eligible applicant was The Carter Center, identified as a 501(c)(3) charitable organization.
Was this an open competition for multiple organizations?
No. The notice stated that no other applications were solicited, meaning it functioned as a directed cooperative agreement rather than an open competitive opportunity.
Why did the announcement effectively function as a sole-eligible-applicant opportunity?
Based on the eligibility restriction and the statement that no other applications were solicited, the structure indicates the CDC viewed The Carter Center as uniquely positioned to carry out OEPA-aligned elimination work at the required scale and with the necessary partnerships, experience, and regional footprint.
How was this opportunity connected to broader U.S. global health goals?
It was framed as supporting the Global Health Initiative (GHI) target of eliminating onchocerciasis in Latin America by 2016.
What phase of elimination work was this funding intended to support?
The funding was designed for late-stage (endgame) elimination tasks, including sustaining high-coverage ivermectin distributions where transmission risk persisted, tightening operational quality, and expanding the intensity and rigor of surveillance as areas approached stopping treatment and moving into post-treatment monitoring.
When was the opportunity posted and when did it close?
It was posted and created on December 13, 2011. The original and current closing date was January 17, 2012.
Is this funding opportunity still active?
No. The archive date was February 16, 2012, indicating it is no longer active.
What CFDA number was associated with this program?
The CFDA number associated with the program was 93.283 (CDC Investigations and Technical Assistance).
Who was listed as the contact for technical issues accessing the full announcement?
The contact listed for technical issues was the CDC Procurement and Grants Office Technical Information Management Section (TIMS) at 770-488-2700.
What kinds of questions was the listed contact intended to address?
The listed contact was presented as a channel for technical issues accessing the announcement materials, rather than for programmatic questions.
Browse more opportunities from the same category: Health
Next opportunity: Intertribal Workshop Facilitator for Montana and South Dakota
Previous opportunity: North Coast Bay and Dunes Outreach and Snowy Plover Education Program
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for CDC RFA GH12 1202
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (CDC RFA GH12 1202) also looked into and applied for these:
| Funding Opportunity |
|---|
| Conducting Public Health Research in South Africa by the National Health Laboratory Service (NHLS) Apply for RFA GH 12 004 Funding Number: RFA GH 12 004 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $5,000,000 |
| Partnerships for Development of Therapeutics and Diagnostics for Biodefense (R01) Apply for RFA AI 12 017 Funding Number: RFA AI 12 017 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Epidemiology, Prevention and Treatment of Influenza and Other Respiratory Infections in Ghana Apply for RFA IP 12 001 Funding Number: RFA IP 12 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Studies at the Animal Human Interface of Influenza and Other Zoonotic Diseases in Vietnam Apply for RFA IP 12 002 Funding Number: RFA IP 12 002 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Epidemiology, Prevention and Treatment of Influenza and Other Respiratory Infections in Panama and Central America Region Apply for RFA IP 12 006 Funding Number: RFA IP 12 006 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Morris K. Udall Centers of Excellence for Parkinsons Disease Research (P50) Apply for RFA NS 12 009 Funding Number: RFA NS 12 009 Agency: National Institutes of Health Category: Health Funding Amount: $1,500,000 |
| Research Dissemination and Implementation Grants (R18) Apply for PAR 12 063 Funding Number: PAR 12 063 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Public Health Conference Support Program Apply for CDC RFA EH12 1201 Funding Number: CDC RFA EH12 1201 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
| Research Grants for Preventing Violence and Violence Related Injury Apply for RFA CE 12 002 Funding Number: RFA CE 12 002 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $400,000 |
| Identifying Modifiable Protective Factors for Intimate Partner Violence or Sexual Violence Prevention Apply for RFA CE 12 003 Funding Number: RFA CE 12 003 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $350,000 |
| Regional Genetic and Newborn Screening Services Collaboratives Heritable Disorders Program Apply for HRSA 12 138 Funding Number: HRSA 12 138 Agency: Health Resources and Services Administration Category: Health Funding Amount: $600,000 |
| Healthy Start Initiative Eliminating Disparities in Perinatal Health (General Population) Apply for HRSA 12 016 Funding Number: HRSA 12 016 Agency: Health Resources and Services Administration Category: Health Funding Amount: $750,000 |
| Healthy Start Initiative Eliminating Disparities in Perinatal Health (Border, Alaska, and Hawaii) Apply for HRSA 12 017 Funding Number: HRSA 12 017 Agency: Health Resources and Services Administration Category: Health Funding Amount: $750,000 |
| Green Housing Study Follow up Measurements of Housing Factors and Respiratory Health of Children located in Cincinnati and Boston (U01) Apply for RFA EH 12 001 Funding Number: RFA EH 12 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $350,000 |
| HIV Early Intervention Services (EIS) Program Existing Geographic Service Areas (EISEGA) Apply for HRSA 12 076 Funding Number: HRSA 12 076 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Reducing Health Disparities among People with Intellectual Disabilities Apply for RFA DD 12 003 Funding Number: RFA DD 12 003 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $250,000 |
| Service Area Competition Additional Areas (Boydton, VA) Apply for HRSA 12 168 Funding Number: HRSA 12 168 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| State Implementation Grants for Systems of Services for Children and Youth with Special Health Care Needs (CYSHCN) Apply for HRSA 12 049 Funding Number: HRSA 12 049 Agency: Health Resources and Services Administration Category: Health Funding Amount: $300,000 |
| New England Region AIDS Education and Training Center Program(s) (AETC) Apply for HRSA 12 124 Funding Number: HRSA 12 124 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Network and Infrastructure Support for Development of Interdisciplinary Aging Research (R24) Apply for PA 12 064 Funding Number: PA 12 064 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "CDC RFA GH12 1202", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.